KLK3 and pachyonychia congenita: Currently, the identification of non-invasive markers in PC patients treated with new hormonal drugs, such as enzalutamide, is the object of much of the translational research carried out into this area, and NLR could, like PSA, prove to be an important factor to monitor treatment in PC patients.